logowsbdaily | Tue, 20 Dec 2022 03:11:27 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Provention Bio, Inc.
(PRVB)

Provention Bio, Inc.
55 Broad Street
2nd Floor Red Bank
Red Bank, NJ 07701
United States
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the pre... Read More

Summary & Charts

Price$ 8.41+1.74 (+26.08%)
Day's Range$ 7.11 - 9.10 
Previous Close$ 6.67
Market Cap$ 685.83M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqGS
IndustryBiotechnology
SectorHealthcare
Volume16.46M
Avg. Volume (20 day)2.22M
Rel. Volume (20 day)7.43
Rel. Volume (3 month)11.60
RatingBNeutral
DCFN/AStrong Buy
Debt/Equity33.95 %Neutral
ROE-99.08 %Sell
ROA-54.72 %Sell
P/E-6.59 %Strong Sell
P/B4.83 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Nov 03, 2022$ 7.54$ 9.10$ 7.11$ 8.41+1.7416,463,0177.4311.60
Nov 02, 2022$ 6.86$ 7.04$ 6.62$ 6.67-0.181,163,1410.621.00
Nov 01, 2022$ 7.00$ 7.19$ 6.83$ 6.85-0.09788,8740.430.69
Oct 31, 2022$ 6.70$ 6.99$ 6.46$ 6.94+0.27881,8250.480.77
Oct 28, 2022$ 6.49$ 6.79$ 6.38$ 6.67+0.191,311,9640.731.17
Oct 27, 2022$ 6.65$ 6.79$ 6.44$ 6.48-0.101,049,8850.600.96
Oct 26, 2022$ 6.70$ 6.97$ 6.53$ 6.58-0.10941,1860.550.87
Oct 25, 2022$ 6.63$ 7.12$ 6.63$ 6.68+0.011,456,5150.861.38
Oct 24, 2022$ 6.77$ 6.83$ 6.54$ 6.67-0.10778,7800.470.75
Oct 21, 2022$ 6.97$ 7.00$ 6.73$ 6.77-0.15900,4140.550.88
Oct 20, 2022$ 6.66$ 7.04$ 6.60$ 6.92+0.21720,6870.450.71
Oct 19, 2022$ 6.73$ 7.00$ 6.63$ 6.71+0.01660,3350.410.65
Oct 18, 2022$ 6.51$ 6.84$ 6.50$ 6.70+0.341,096,6010.691.07
Oct 17, 2022$ 7.02$ 7.14$ 6.35$ 6.36-0.551,841,6751.171.80
Oct 14, 2022$ 7.12$ 7.50$ 6.87$ 6.91-0.21801,7120.520.791
Oct 13, 2022$ 6.72$ 7.15$ 6.72$ 7.12+0.05935,5350.590.92
Oct 12, 2022$ 7.11$ 7.25$ 6.86$ 7.071,025,8470.651.01
Oct 11, 2022$ 7.70$ 7.90$ 6.73$ 7.07-0.692,079,5931.332.051
Oct 10, 2022$ 7.05$ 7.88$ 6.77$ 7.76+0.843,297,1312.183.301
Oct 07, 2022$ 6.22$ 7.13$ 6.19$ 6.92+0.706,119,4764.336.34

News

The latest news about Provention Bio, Inc. (PRVB).

InvestorPlace | 2022-11-03 15:34:14
It may be a mixed session for the overall market on Thursday, but not for Provention Biosciences (NASDAQ: PRVB ). That's as PRVB stock is up 25% so far in the session and hitting its highest level since July 2021.
Zacks Investment Research | 2022-11-03 09:47:55
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 26.09% and 13.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research | 2022-10-07 13:33:08
Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.
Zacks Investment Research | 2022-10-07 09:47:13
Provention Bio, Inc. (PRVB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Motley Fool | 2022-10-06 09:19:00
Get an early start on the events of the day.
The Motley Fool | 2022-09-22 10:53:00
It could be a make-or-break end of the year for the company.
PRNewsWire | 2022-09-06 16:01:00
RED BANK, N.J. , Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-11-03BMO-0.46----0.8M0.8M-3.08%
2022-08-04BMO-0.5-0.468%------
2022-05-05BMO-0.47-0.3525.54%0.7M0.6M-20.34%
2022-02-24BMO-0.45-0.418.89%0.6M0.7M28.03%
2021-11-04BMO-0.47-0.438.52%1.3M0.7M-45.76%
2021-08-05BMO-0.51-0.469.81%1.4M----
2021-05-06BMO-0.46-0.5213.04%------
2021-02-25BMO-0.5-0.5816%------

Due Diligences

These posts should include more in-depth research by the poster about the specific company, sector or trade idea. Including any sources and citations.

PRVB Provention Bio

This stock has been very near and dear to me vs my regular trading. My daughter was diagnosed T1D a few years back and while there was nothing we could do to prevent or reverse this disease there was a clinical trial I found that was being conducted that showed promising future hope to protect what... Read More

10 comments | 5 votes

Top Discussions

These are the top discussions over the last 24-hours that mention the PRVB stock ticker symbol.


Unusual Option Activity

Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.

TypeStrikeExp DateDTEBidAskLastVolumeOpen InterestVol/OIIV
PUT$ 10.0011/17/2213$ 2.25$ 2.60$ 2.4542261.622.03%
CALL$ 10.0012/15/2241$ 1.00$ 1.25$ 1.121,0291885.471.46%
CALL$ 10.0004/20/23167$ 1.90$ 2.25$ 2.27287377.761.15%
CALL$ 12.5001/18/24440$ 2.60$ 3.30$ 3.008183792.161.10%
Last Updated: Thu, 3 Nov 2022 21:24 EST

Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.